Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone Medical Center, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
Adams says this is a powerful combination. The anti-CTLA4 agent helps to unleash the immune response and invigorates the response, while anti-PD-L1 agents can further stimulate the T cell response. Overall, these are powerful immunotherapeutics, Adams says, and have demonstrated their ability in other cancers, such as melanoma.
In breast cancer, anti-PD-L1 therapy has already been approved for the treatment of patients with triple-negative breast cancer, but there is no approval for routine use of this therapy in breast cancer. These agents also tend to carry some toxicity, so Adams says she tries to limit use of this therapy to patients in trials that have poor prognosis.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More